We conclude that plasma ChT activity and CCL18/PARC concentration measurements in patients with suspected NP-C based on their clinical symptomatology can help pave the way to conducting specific, confirmatory laboratory tests. This evidence concerns the gene SLC5A7 and nasopharyngeal carcinoma.